Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy

Phuong K. Morrow, Stephen Divers, Louise Provencher, Shiuh Wen Luoh, Teresa M. Petrella, Marius Giurescu, Thomas Schmelter, Yao Wang, Gabriel N. Hortobagyi, Linda T. Vahdat

    Research output: Contribution to journalArticle

    16 Scopus citations


    Sagopilone is a novel, fully synthetic epothilone that has shown promising preclinical activity in a range of tumor models, including platinum-resistant ovarian cancer and metastatic breast cancer (MBC). This openlabel, multicenter, Phase II study investigated the efficacy, safety, and tolerability of sagopilone administered to patients with MBC. Women with MBC whose previous chemotherapy regimen included a taxane and an anthracycline received sagopilone 16 or 22 mg/m 2 as a 3-h intravenous infusion every 21 days. Efficacy (using modified Response Evaluation Criteria in Solid Tumors), safety, and tolerability were assessed in this population. A total of 65 patients received sagopilone at either 16 mg/m2 (N = 39) or 22 mg/m 2 (N = 26). Patients received a median of two cycles of sagopilone. Among the 65 patients who were evaluable for efficacy, there were three confirmed tumor responses over both treatment arms; however, the primary target of the study was not reached. The main treatment-related adverse events were sensory neuropathy (81.5%) and fatigue (44.6%). There were no deaths related to the study drug. Sagopilone was moderately tolerated in both treatment arms and showed limited activity in heavily pre-Treated patients with MBC.

    Original languageEnglish (US)
    Pages (from-to)837-842
    Number of pages6
    JournalBreast Cancer Research and Treatment
    Issue number3
    StatePublished - Oct 1 2010



    • Breast cancer
    • Epothilones
    • Metastatic
    • Phase II
    • Sagopilone

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this